AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06600477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 7.5 mg
Study NCT05975476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
Study NCT05975476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Engagement
Description: Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
Study NCT06617312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: Targets α4β2 nicotinic acetylcholine receptors
Study NCT06617312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Matched to active drug, cytisinicline
Study NCT06704555 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: received radiation (dose:18～24Gy)
Study NCT06704555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiselizumab
Description: 200 mg iv day 1
Study NCT06704555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenous \[IV\] day 2
Study NCT06704555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV day 3
Study NCT06704555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV day 3
Study NCT06704555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3
Study NCT06704555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg oral days 3-7
Study NCT06705686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-9bMS
Description: (R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
Study NCT06706375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using ultrasound for penile nerve block
Description: 30% of men over the age of fifteen worldwide have had a circumcision according to a World Health Organization report. (1) This operation is common and should not be trivialized. A certain number of surgical complications should be considered, including pain, infections, excessive bleeding or hematomas. (1,2) Today, the use of opioids as intra- and postoperative analgesics in pediatric urological surgery remains predominant (3) but is the subject of increasing controversies. Indeed, the recent opioid crisis challenges us about their use and highlights their multiple side effects. First of all, their use involves significant risks, (4) including opioid-induced hyperalgesia and potential long-term effects. An increase in pain sensitivity within the 24 postoperative hours being proportional to intraoperative administration of high doses of opioids can be observed. (5) Long-term addiction is also questioned. Then, opioids don't appear to be the most effective per- and postoperative analgesi
Study NCT06706375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Penile Block Anesthesia using landmarks
Description: Dorsal penile nerve block (DPNB) is LRA technique of choice for circumcisions and aims to anesthetize both dorsal penile nerves. (10-12) The name DPNB is used for blocks performed by determining precise dorsal anatomical landmarks and doing two distinct injections.
Study NCT05608434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floreo Virtual Reality application
Description: Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, working memory, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
Study NCT06381934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard diagnosis and therapy procedures at physician's discretion.
Study NCT06381934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aSID/ChU Guided Therapy
Description: Stopping of thiazide therapy. Measure aSID:~* aSID between 39 and 42 mmol/l : measure ChU~  * ChU lower than 15mmol/l : fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~ * ChU higher than 14.9 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~* aSID higher than 42 mmol/l : fuid administration (fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~* aSID lower than 39 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~The aSID/ChU guided therapy will take place for a minimum of 1- and a maximum of 3 days after enrolment. Treatment and adherence to the treatment will be assessed and re-evaluated at least daily for 3 days or till discharge or sodium normalization.
Study NCT05429216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mEMR-C procedure
Description: A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
Study NCT05429216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD procedure
Description: ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
Study NCT04823585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
Study NCT04823585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution. Subcutaneous.
Study NCT05037240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Quercetin (500 mg), 2 times a day for 3 months
Study NCT05037240 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg, 2 times a day for 3 months
Study NCT05245435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT-PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
Study NCT05245435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: liquid biopsies
Description: circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
Study NCT06399406 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Medi-TBS
Description: The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
Study NCT06399406 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Medi-TBS
Description: The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
Study NCT05027594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
Study NCT05027594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812 + dexamethasone
Description: All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
Study NCT05025839 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention takes place, Patients are being observed and classified according to disease severity
Study NCT05862753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction by Etomidate bolus
Description: General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
Study NCT05805631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal Pemetrexed
Study NCT05861076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Powder - Low Dose
Description: 1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
Study NCT05861076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Powder - Medium Dose
Description: 2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
Study NCT05861076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moringa Powder - High Dose
Description: 3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
Study NCT04813588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pantomiming
Description: Pantomiming with fluency shaping techniques
Study NCT04813588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Easy onset
Description: Easy onset method with breathing exercises
Study NCT05398744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Exercise Program
Description: At-home, aerobic group exercise program facilitated by exercise physiologist via video format, 3 times a week for 16 weeks.
Study NCT04734639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON . control condition without exercise / rest condition
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
Study NCT04734639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.
Description: Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
Study NCT04734639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Def-EI. Condition with an energy-restriction energy deficit
Description: Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
Study NCT04715620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight \<77Kg or baseline platelet count \<150,000/µL)
Study NCT05647135 — intervention group
Intervention type: OTHER
Intervention: Medical food
Description: enteral formulas with different protein composition
Study NCT05482308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Test)
Description: Variant 12.2 mg tafamidis free acid tablet (Test)
Study NCT05482308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Reference)
Description: Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
Study NCT05020821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-shot superior trunk block with intravenous dexmedetomidine
Description: During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
Study NCT05020821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous superior trunk block
Description: During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
Study NCT04199221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Innoculation Training (SIT)
Description: 1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
Study NCT04199221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extra attempt
Description: an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
Study NCT04199221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra attempt
Description: an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
Study NCT06285435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: prothrombin fragment 1+2
Description: Blood sample
Study NCT05034367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Description: Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
Study NCT05883969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GO-PLAY
Description: The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
Study NCT05883969 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
Study NCT05851651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal milk expression and breastfeeding self-efficacy enhancement
Description: A face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation will be arranged. The session will approximately last for 45minutes. GDM leaflet and GAME fact sheet are used to facilitate the teaching. The benefits of breastfeeding for women with GDM will be addressed. Maternal metabolic control, calories consumed, and weight loss are addressed for the extra benefits of breastfeeding for GDM women. The possible challenges of GDM on breastfeeding will be supported. The antenatal human milk expression will be taught by International Board-Certified Lactation Consultant. Participants will be encouraged to express colostrum twice daily for up to 10 minutes until admitted to hospital to give birth. They will receive a weekly phone follows up from 38 weeks before delivery and they can contact the researcher by phone in the information sheet if any questions.
Study NCT05119036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 44 doses of radiation
Description: Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
Study NCT05119036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 54 doses of radiation
Description: Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
Study NCT04896866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship prospective audit and feedback
Description: Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
Study NCT05808686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
Study NCT05808686 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ischemic Conditioning
Description: We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.